Does Dose-dense Chemotherapy Improve Outcomes for Patients With High-risk Early Breast Cancer?
Dose-dense chemotherapy is not associated with an improvement in recurrence-free survival among patients with early-stage, high-risk breast cancer.
All articles by Jibin Mathew
Bosutinib for CML After Progression With First-line TKI
Bosutinib has shown promise in patients with Philadelphia-positive (Ph+) chronic phase chronic myeloid leukemia (CML-CP).
The Use of Telotristat Ethyl for the Treatment of Carcinoid Syndrome
Telotristat ethyl, a tryptophan hydroxylase inhibitor, may be beneficial for patients with carcinoid syndrome.
- Loading...
Loading...
Loading... 
Loading...